Antares Pharma to Present at the Jefferies 2015 Global Healthcare Conference
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/28/2026
- Stocks fall as higher oil prices, Treasury yields weigh
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Nvidia’s AI dominance funds historic $150 billion buyback
- MongoDB stock drops 15% as CEO Desai resigns for Meta
- Jefferies cuts Roblox to Underperform, says rally is too optimistic
Antares Pharma (ATRS) Receives Response from FDA on QuickShot Testosterone Program; Will Need Additional Data
June 1, 2015 7:06 AM EDTAntares Pharma (NASDAQ: ATRS) announced that it has received a written update from the U.S. Food and Drug Administration (FDA) related to its clinical development program for QuickShot Testosterone (QS T) that the Company believes is consistent with its previously disclosed interpretation of the advice letter received from FDA in January 2015. As previously disclosed, the Company received an advice letter from FDA in January 2015 regarding various clinical, CMC (Chemistry,... More
